For the first time in history, infants under 5 kilograms — the smallest and most fragile newborns — have a malaria treatment designed specifically for them. Regulators approved Coartem Baby, a dissolvable, cherry-flavored formulation of an existing antimalarial drug, correctly dosed for babies who previously had no approved option at all. It is a quiet but profound shift in what medicine can offer the world’s most vulnerable patients.
At a glance
- Newborn malaria treatment: Coartem Baby is the first antimalarial drug approved specifically for infants weighing under 5 kg, developed through a partnership between pharmaceutical company Novartis and the non-profit Medicines for Malaria Venture (MMV).
- Regulatory pathway: Swiss regulator Swissmedic granted approval and fast-tracked the process for eight African countries — Burkina Faso, Côte d’Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda — all of which participated in clinical trials.
- Newborn malaria treatment access: Novartis has committed to providing the drug on a largely not-for-profit basis, prioritizing availability in the malaria-endemic regions where need is greatest.
A gap that lasted decades
Until now, newborns under 5 kilograms occupied a blind spot in malaria medicine. No approved drug existed for them.
Clinicians and caregivers often made do with formulations designed for older, heavier children — a workaround that carried real risks of incorrect dosing and toxicity. That gap persisted for decades, even as malaria killed hundreds of thousands of young children every year. According to the World Health Organization, children under five account for roughly three-quarters of all malaria deaths in Africa. Newborns were also excluded from malaria vaccines, which are not yet approved for the youngest infants.
Coartem Baby fills that gap directly — giving frontline health workers their first purpose-built option for their smallest patients.
How a public-private partnership made it happen
The development of Coartem Baby reflects a model of global health cooperation that is still relatively new. Novartis partnered with MMV, a non-profit focused entirely on antimalarial drug development, to work out the precise dose and ingredient ratio safe for newborns — then design a formulation those babies could actually take: dissolvable, sweet, and easy to administer without a syringe or tablet.
The regulatory strategy was equally deliberate. By running clinical trials across eight African countries and seeking initial approval through Swissmedic, the partnership created a pathway for rapid national approvals in exactly the places where the drug is needed most. This kind of coordinated approach — linking research, regulation, and access in a single pipeline — has historically been difficult to achieve in global health.
It also echoes broader progress in closing equity gaps in medicine. The rollout of malaria vaccines across sub-Saharan Africa through similar public-private cooperation showed what was possible when multiple institutions align around a shared goal. Coartem Baby follows that logic, but targets the window of life the vaccines cannot yet reach.
What it means on the ground
Health workers in rural and remote communities carry most of the burden of diagnosing and treating malaria in young children. Many operate with limited supplies, inconsistent cold chains, and no specialist backup. A correctly dosed drug that is easy to administer and available at low cost changes what those workers can offer in a critical moment.
Malaria remains one of the most preventable causes of child death globally. Programs backed by the CDC and WHO have driven significant reductions in transmission over two decades through insecticide-treated bed nets and indoor spraying campaigns. Treatment options have improved for older children and adults. But the youngest infants — those born into high-transmission environments during the most fragile weeks of life — had been left without a safe, approved answer.
Coartem Baby adds a new and specific layer to that protection. Its existence, where nothing approved existed before, is a measurable advance for children whose lives are most at risk in the first weeks after birth.
What still needs to happen
Approval is a milestone, not a guarantee of impact. Getting Coartem Baby to the communities that need it will require sustained supply chains, trained health workers, and continued funding — none of which is automatic. Distribution infrastructure in some of the eight participating countries remains fragile, and broader rollout beyond those nations will take additional time and resources. The not-for-profit pricing commitment is a meaningful signal, but access to medicines in remote settings depends on far more than price alone.
Still, the drug exists now. That is new. And for the infants it was built for, that changes everything.
Read more
For more on this story, see: Euronews
For more from Good News for Humankind, see:
- Ghana protects a stretch of Atlantic coastline with a new marine area
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
